Verrica Pharmaceuticals Inc. (VRCA)Healthcare | Biotechnology | West Chester, United States | NasdaqCM
3.83 USD
+0.25
(6.983%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 3.83 +0.00 (0.104%) ⇧ (Oct. 14, 2026, 6:53 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:01 a.m. EDT
The investment case for Verrica Pharmaceuticals is currently compromised by severe structural deterioration and a complete lack of income generation. Fundamentally, the company is in a deep freefall, having lost over 97% of its value over the past seven years. While the most recent annual data shows two consecutive years of decline rather than a longer streak, the trajectory is unmistakably negative, driven by a massive contraction in revenue (-54%) and persistent losses. The balance sheet is fragile, with negative free cash flow and a price-to-book ratio of 16x, suggesting the market views the current equity value as a liability relative to assets. Despite a 'Strong Buy' analyst recommendation and a lofty $20 price target, these figures appear disconnected from the harsh reality of the underlying business metrics. The recent news of a potential deal in Israel offers a glimmer of hope, but it is insufficient to counteract the multi-year trend of value destruction. From a trading perspective, the sentiment is overwhelmingly bearish; options data reveals a heavy concentration of put buying, with traders actively hedging against further drops while virtually ignoring upside potential. With no dividend to provide any cushion and a statistical forecast leaning slightly negative, the short-term outlook remains precarious. Investors should view this as a high-risk speculative play on a binary clinical outcome rather than a viable investment vehicle. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.074032 |
| AutoETS | 0.088042 |
| AutoARIMA | 0.089271 |
| MSTL | 0.090054 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 5.01 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.652 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 42.025 |
| Revenue per Share | 1.831 |
| Market Cap | 65,794,756 |
| Forward P/E | -2.59 |
| Beta | 1.61 |
| Profit Margins | -102.84% |
| Website | https://www.verrica.com |
As of Oct. 10, 2026, 6:01 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts expiring in December at strikes below the current price. Conversely, call activity is negligible, with minimal interest even in near-term out-of-the-money strikes, indicating a lack of speculative bullishness.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12682927 |
| Address1 | 44 West Gay Street |
| Address2 | Suite 400 |
| All Time High | 232.9 |
| All Time Low | 3.28 |
| Ask | 5.91 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 48,680 |
| Average Daily Volume3 Month | 64,728 |
| Average Volume | 64,728 |
| Average Volume10Days | 48,680 |
| Beta | 1.606 |
| Bid | 3.4 |
| Bid Size | 2 |
| Book Value | 0.251 |
| City | West Chester |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.83 |
| Current Ratio | 1.454 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.92 |
| Day Low | 3.5 |
| Debt To Equity | 42.025 |
| Display Name | Verrica Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,600,000 |
| Earnings Timestamp Start | 1,794,600,000 |
| Ebitda | -25,964,000 |
| Ebitda Margins | -0.8563 |
| Enterprise To Ebitda | -2.007 |
| Enterprise To Revenue | 1.719 |
| Enterprise Value | 52,112,052 |
| Eps Current Year | -1.965 |
| Eps Forward | -1.4775 |
| Eps Trailing Twelve Months | -1.75 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.8022 |
| Fifty Day Average Change | -0.9721999 |
| Fifty Day Average Change Percent | -0.20244886 |
| Fifty Two Week Change Percent | -12.682926 |
| Fifty Two Week High | 9.821 |
| Fifty Two Week High Change | -5.991 |
| Fifty Two Week High Change Percent | -0.6100194 |
| Fifty Two Week Low | 3.28 |
| Fifty Two Week Low Change | 0.54999995 |
| Fifty Two Week Low Change Percent | 0.16768292 |
| Fifty Two Week Range | 3.28 - 9.821 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,069,400,000 |
| Float Shares | 12,405,660 |
| Forward Eps | -1.4775 |
| Forward P E | -2.5922165 |
| Free Cashflow | -9,037,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Fullday Change | 0.26999998 |
| Fullday Change Percent | 7.541899 |
| Fullday Price | 3.834 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.3768 |
| Gross Profits | 11,425,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.48997003 |
| Held Percent Institutions | 0.27144 |
| Implied Shares Outstanding | 17,178,787 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,753,401,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. |
| Long Name | Verrica Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 65,794,756 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_319720251 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -31,183,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 80,224,930 |
| Number Of Analyst Opinions | 6 |
| Open | 3.54 |
| Operating Cashflow | -13,347,000 |
| Operating Margins | -1.9445599 |
| Phone | 484 453 3300 |
| Post Market Change | 0.004000187 |
| Post Market Change Percent | 0.10444353 |
| Post Market Price | 3.834 |
| Post Market Time | 1,792,018,382 |
| Previous Close | 3.58 |
| Price Eps Current Year | -1.9491093 |
| Price Hint | 4 |
| Price To Book | 15.258965 |
| Price To Sales Trailing12 Months | 2.1699402 |
| Profit Margins | -1.02843 |
| Quick Ratio | 0.993 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | 0.25 |
| Regular Market Change Percent | 6.9832406 |
| Regular Market Day High | 3.92 |
| Regular Market Day Low | 3.5 |
| Regular Market Day Range | 3.5 - 3.92 |
| Regular Market Open | 3.54 |
| Regular Market Previous Close | 3.58 |
| Regular Market Price | 3.83 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 53,958 |
| Return On Assets | -0.43982 |
| Revenue Growth | -0.539 |
| Revenue Per Share | 1.831 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 17,178,786 |
| Shares Percent Shares Out | 0.0114 |
| Shares Short | 196,221 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 222,572 |
| Short Name | Verrica Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0222 |
| Short Ratio | 3.79 |
| Source Interval | 15 |
| State | PA |
| Symbol | VRCA |
| Target High Price | 20.0 |
| Target Low Price | 9.0 |
| Target Mean Price | 13.83333 |
| Target Median Price | 12.5 |
| Total Cash | 11,198,000 |
| Total Cash Per Share | 0.652 |
| Total Debt | 1,810,000 |
| Total Revenue | 30,321,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.9071 |
| Two Hundred Day Average Change | -2.0771003 |
| Two Hundred Day Average Change Percent | -0.35162774 |
| Type Disp | Equity |
| Volume | 53,958 |
| Website | https://www.verrica.com |
| Zip | 19,380 |